Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price rose 4.1% during trading on Wednesday . The stock traded as high as $2.11 and last traded at $2.05. Approximately 184,975 shares changed hands during trading, a decline of 70% from the average daily volume of 620,672 shares. The stock had previously closed at $1.97.
Cortexyme Price Performance
The firm’s 50 day moving average is $1.50 and its 200 day moving average is $1.00. The firm has a market cap of $61.21 million, a P/E ratio of -0.68 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- Buy P&G Now, Before It Sets A New All-Time High
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Using the MarketBeat Stock Split Calculator
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Buy Cheap Stocks Step by Step
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
